(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Illustrations Gained from a Crosscountry Excursion - 2We may have less control over how long we live than previously thought
- 3A definitive Frozen yogurt Standoff: Which Flavor Rules?
- 4Doomed SpaceX Starlink satellite photographed from orbit
- 5Moon-bound Artemis II astronauts enjoy a relaxed day in space
- This Week In Space podcast: Episode 192 — Space, 2026!
- A Lone Wolf Outsmarted Hunters in the Black Forest and Then Vanished
- Must-Have Wellness Gear: What to Purchase for Successful Exercises
- What you need to know about Trump accounts as Michael and Susan Dell donate $6 billion to the new early childhood investment program
- Foot fossil discovery could reshape human evolutionary history
- Surveys of Music Collections by Film Stars
- Bitcoin momentum builds in Abu Dhabi as global interest surges
- Some gifted dogs can learn new toy names by eavesdropping on owners
- Investigating Remarkable Espresso Flavors: Upgrade Your Day to day Blend
